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Background: Approximately twenty percent of lymph node (LN) negative non-small cell lung cancer 
(NSCLC) patients who undergo curative intent surgery have pan-cytokeratin immunohistochemistry 
(IHC)-detectable occult micro-metastases (MMs) in resected LNs. The presence of the MMs in NSCLC 
is associated worsened outcomes. As a substantial proportion of NSCLC LN staging is conducted using 
endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA), we sought to determine 
the frequency of detection of occult MMs in EBUS-TBNA specimens and to evaluate the impact of MMs on 
progression-free and overall survival.
Methods: We performed retrospective IHC staining for pan-cytokeratin of EBUS-TBNA specimens 
previously deemed negative by a cytopathologist based on conventional hematoxylin and eosin staining. The 
results were correlated with clinical variables, including survival outcomes.
Results: Of 887 patients screened, 44 patients were identified meeting inclusion criteria with sufficient 
additional tissue for testing. With respect to the time of the EBUS-TBNA procedure, 52% of patients were 
clinical stage I, 34% clinical stage II, and clinical 14% stage IIIa NSCLC. Three patients (6.8%) were found 
to have cytokeratin positive MMs. All 3 MMs detected were at N2 LN stations. The presence of MMs was 
associated with significantly decreased progression-free (median 210 vs. 1,293 days, P=0.0093) and overall 
survival (median 239 vs. 1,120 days, P=0.0357).
Conclusions: Occult LN MMs can be detected in EBUS-TBNA specimens obtained during staging 
examinations and are associated with poor clinical outcomes. If prospectively confirmed, these results have 
significant implications for EBUS-TBNA specimen analyses and possibly for the NSCLC staging paradigm.
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Introduction
Non-smal l  ce l l  lung cancer  (NSCLC) remains  a 
disproportionate cause of cancer mortality relative to 
its incidence (1). One of the many treatment challenges 
associated with NSCLC is the frequency of recurrence 
following definitive treatment of early stage disease (2-5). 
Using immunohistochemistry (IHC) staining for 
pancytokeratin, lymph node (LN) micro-metastases (MMs) 
have been demonstrated in patients with NSCLC deemed 
to have negative LNs by conventional hematoxylin and 
eosin (H+E) staining. The presence of LN MM has long 
been associated with worsened outcomes in NSCLC 
patients (6). Subsequent work focused on detection of MM 
in NSCLC using IHC staining for Ber-Ep4/Ep-CAM, and 
MMs were detected in 15.2% to 31.2% of patients (7-9). 
Recently, two large prospective trials reported detection 
of LN MMs in 22% and 14% of early stage NSCLC 
patients, and in both studies LN MMs had an association 
with worsened clinical outcomes (10,11). Micrometastases 
have been suggested as one possible explanation for the 
relatively poor outcomes of definitively surgically treated 
NSCLC patients (6-11). 
Endobonchial ultrasound with transbronchial needle 
aspiration (EBUS-TBNA) or similar needle aspiration 
techniques are currently recommended as the first line 
invasive mediastinal staging modality in patients with a 
high incidence of N2 or N3 disease (12). In addition, many 
early stage NSCLC patients have comorbidities which 
preclude definitive surgery or are unwilling to undergo 
surgery (13,14). A substantial number of these patients 
are treated with stereotactic body radiotherapy (SBRT) or 
conventionally fractionated therapy as definitive treatment, 
procedures which do not directly involve detailed sampling 
of local LNs (15-17). Positron emission tomography (PET) 
may not be sufficient to adequately stage patients being 
considered for definitive radiation therapy and invasive 
mediastinal staging with EBUS may have a role in pre-
radiation treatment planning (18,19). As such, EBUS-
TBNA has a substantial role in the pre-treatment staging in 
a large proportion of lung cancer patients, even those with 
putative early stage disease.   
The incidence of IHC-detectible LN MMs in patients 
with NSCLC as detected by EBUS-TBNA is unknown. 
Given the paucity of data in this realm and the first line role 
of EBUS-TBNA in mediastinal assessment in many clinical 
situations for NSCLC, we retrospectively evaluated the 
incidence of IHC detectable LN MMs in EBUS-TBNA 
specimens obtained for lung cancer staging purposes and 
correlated the results with clinical outcomes 
Methods
Patient identification
All patients undergoing EBUS-TBNA for NSCLC LN 
staging at the University of North Carolina between 
September of 2013 and October 2017 were eligible for 
study inclusion. Staging indications at our institution 
include enlarged LNs on cross-sectional imaging, PET 
positivity of a LN, central tumor location (within 2/3 
of the distance to the pleura from the mediastinum), or 
consideration for stereotactic body radiation therapy 
(SBRT) if the patient can tolerate a diagnostic procedure. 
These indications are slightly modified from the those 
recommended by the American College of Chest Physicians 
guidelines (12). Patients were identified using provider-
maintained case lists, operating room or procedure room 
electronic schedules, and tumor board patient presentations. 
Defined blocks of 7.5 to 23 months were evaluated for each 
EBUS-TBNA provider (JA, MPR, JL, BH) during which 
time each EBUS-TBNA case performed was evaluated for 
inclusion. The blocks were selected based on convenience 
with respect to the availability of case lists from the EBUS-
TBNA attending providers (JA, MPR, JL, BH). All patients 
undergoing a procedure during a defined block were 
evaluated. Patient identification continued until the funding 
for the study was exhausted. Patients presented to the lung 
cancer tumor board fitting study inclusion criteria while 
cases were being identified (Jan 2016 to Oct 2017) were also 
screened for inclusion. 
Regardless of the method of identification, all identified 
patients were screened for study inclusion. Patients were 
required to have undergone an EBUS-TBNA procedure of 
at least one LN station for staging of suspected NSCLC. 
Tissue diagnosis confirming NSCLC was required within 
3 months of performance of EBUS-TBNA. It was not 
required that the diagnosis of NSCLC be obtained after 
the EBUS-TBNA was performed (a few patients were 
included who had a CT-guided biopsy of a nodule which 
was positive for NSCLC and then went on for EBUS-
TBNA staging). Patient wishes regarding treatment were 
not taken into account and thus patients who choose to 
forgo curative intent therapy were not excluded. Patients 
were excluded if no definitive tissue diagnosis of NSCLC 
was obtained within 3 months of initial EBUS-TBNA, if 
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their EBUS-TBNA was positive for N2 or N3 disease by 
conventional H+E staining at any site, or if extrathoracic 
metastatic disease was present at the time of the EBUS-
TBNA. Finally, patients were excluded if their index lung 
lesion was a squamous cell cancer and they had a concurrent 
extrathoracic primary squamous cell cancer and their lung 
lesion could not be reliably differentiated from a metastasis 
by immunohistochemical staining. A prior history of 
NSCLC was not exclusion criteria in patients without a 
concern for local recurrence. This study was approved by 
the University of North Carolina at Chapel Hill Program 
Review Committee and Institutional Review Board (LCCC 
1425 and 14-1755, respectively). 
Specimen acquisition and processing
All patients underwent computed tomography (CT) 
scanning prior to their EBUS-TBNA procedure. Positron 
emission tomography (PET) with CT was performed at 
the discretion of the referring or procedural team. All 
procedures were performed in an operating room setting 
under general anesthesia using a laryngeal mask airway or 
endotracheal tube at the discretion of the anesthesia team. 
Rapid on-site cytologic evaluation (ROSE) was available for 
all cases to determine the presence or absence of obvious 
LN metastasis. All patients underwent a complete airway 
inspection using a standard white light bronchoscope, 
BF-T180 (Olympus; Tokyo, Japan), to evaluate for occult 
endobronchial disease. EBUS-guided evaluation of the 
mediastinal and hilar LNs was performed in a systematic 
fashion starting with the N3 nodes and proceeding in a 
systematic fashion to N2 and N1 nodes. EBUS-TBNA was 
performed for LNs larger than 5 mm in shortest diameter 
using an EBUS bronchoscope, BFUC-180F (Olympus; 
Tokyo, Japan), and a dedicated 21- or 22-g EBUS needle 
(Olympus; Tokyo, Japan) (20). 
Prior to study inclusion, cytologic specimens (slides 
and cell blocks) from the EBUS-TBNA procedure were 
evaluated by a cytopathologist using conventional staining 
according to standard guidelines. After selection for 
inclusion in this study, the smears and cell blocks from 
each TBNA specimen at each biopsied LN station were re-
reviewed by a study pathologist (JH). Samples containing 
only blood were excluded from further review. Cell blocks 
from the included stations were re-sectioned into five 5 µm 
sections for additional study by IHC. 
IHC was carried out in the Bond Autostainer (Leica 
Biosystems Inc., Norwell, MA). Slides were dewaxed in 
Bond Dewax solution (AR9222) and hydrated in Bond 
Wash solution (AR9590). Antigen retrieval was performed 
for 30 min at 100 ℃ in Bond-Epitope Retrieval solution1 
pH-6.0 (AR9961). After pretreatment, the slides were 
incubated with mouse monoclonal anti-human cytokeratin 
(AE1/AE3) (Dako, M3515, Agilent Pathology Solutions, 
Santa Clara, CA 95051) diluted 1:200 for 30 min. Detection 
was performed using Bond™ Polymer Refine Detection 
(DS9800). Stained slides were dehydrated and cover-
slipped. The same positive and negative (no primary 
antibody) control tissues were included for each staining 
batch. All slides were then reviewed for evidence of MMs 
by a pathologist (JH) blinded to the clinical scenario. LN 
MMs were defined as one or more non-bronchial epithelial 
abnormal cells which showed strong membranous positive 
staining for cytokeratin. 
Data abstraction
The date of diagnosis was defined as the date of the first 
positive specimen obtained, either from EBUS-TBNA, 
CT-guided biopsy, navigational bronchoscopy, or surgery. 
Time to progression and time to death are reported with 
respect to the date of diagnosis. The date of death for a 
patient was obtained from either the medical record directly 
or a search of public records. If no record of the patient’s 
death was available, they were censored on the last date 
of contact available through the medical record. Staging 
was determined using the 7th edition of the International 
Association for the Study of Lung Cancer TNM system (21). 
Clinical staging was reported with respect to the date of 
EBUS-TBNA performance (i.e., LN metastases during 
subsequent surgical resection were not included in the 
reported stage). Tumor sizes were abstracted from surgical 
resection specimen reports when available or measurements 
from the most recently available cross-sectional imaging 
with respect to the date of diagnosis.
Statistical considerations
Data collection and analysis was performed using GraphPad 
Prism version 7.04 for Windows (GraphPad Software, La 
Jolla California USA). Data are reported as the absolute 
number and percent of the total for categorical variables, 
the median survival probability and standard error of 
measurement, or the median and interquartile range 
(Q1–Q3) for the remaining continuous variables. Survival 
analysis was performed for overall mortality and progression 
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free survival for all patients and for clinical stage I and II 
patients only using Kaplan-Meier estimates; the survival 
functions were compared using a log-rank test.
Results
A total of 887 patients were screened for study inclusion 
of whom 389 underwent a qualifying EBUS procedure. 
Of the 389 patients identified, 228 patients were excluded 
because the EBUS detected N2 or N3 disease or the patient 
was metastatic at the time of the procedure. An additional 
117 patients were excluded because either a non-malignant 
diagnosis was obtained or no diagnosis of NSCLC was 
obtained in the required 3-month window surrounding 
the EBUS-TBNA, or insufficient tissue was available 
for additional testing. A total 44 patients were identified 
meeting inclusion criteria with sufficient additional tissue 
for testing and were further analyzed.
Patient demographics are summarized in Table 1. The 
study sample contained exclusively Caucasians and African 
Americans. A majority of patients were male. Three patients 
were lifelong non-smokers, however, the vast majority of 
patients had a heavy smoking history. EBUS procedure, 
clinical staging, and treatment data are summarized in Table 2. 
The median number of LN stations sampled during EBUS-
TBNA was 3. Curative intent therapy was attempted in 41 
patients (93%). 
Three patients (6.8%) had detectible MM in their 
EBUS-TBNA specimens (Figure 1). The MMs were found 
in N2 nodes only. The 3 patients found to have MM were 
clinically staged as IA, IB, and IIA; only the stage IIA 
Table 1 Patient demographics and medical history (n=44)
Characteristics Value






African American 11 [25]
Smoking history (pack-years) 50 [30–56]
Prior history of cancer 11 [25]* 
NSCLC 4 [9]
Head and neck SCC 2 [5]




Renal cell cancer 1 [2]
Data are presented as median [quartile 1–quartile 3] or absolute 
number [percent of population]. *, one patient had a history of 
two prior cancers (renal and NSCLC). NSCLC, non-small cell 
lung cancer.












EBUS-TBNA N1 positive LN 5 [11]
LN stations biopsied during EBUS-TBNA 3 [2–3]
Treatment
Surgical resection alone 9 [21]
Surgical resection + chemotherapy 4 [9]
Surgical resection + chemotherapy + conventional RT 1 [2]
Surgical resection + conventional RT 3 [7]
SBRT alone 16 [36]
SBRT + chemotherapy 1 [2]
Conventional RT alone 3 [7]
Conventional RT + chemotherapy 4 [9]
No treatment 3 [7]
Data are presented as median [quartile 1–quartile 3] or absolute 
number [percent of population]. LN, lymph node; EBUS-TBNA,  
endobronchial ultrasound-guided transbronchial needle  
aspiration; RT, radiation therapy; SBRT, stereotactic body  
radiation therapy.
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patient had a tumor larger than 4 cm. The stage IA and 
stage IB patients’ primary tumors were in the right upper 
lobe and the stage IIA patient’s tumor was located in the 
left lower lobe. The clinically-staged IIA patient underwent 
surgical resection during which a positive N2 LN was 
detected (station 9) at the time of resection; the MMs in 
that patient were detected on the EBUS-TBNA specimens 
at station 8 and 11L. This patient was included in the 
survival analysis based on their clinical stage to remain 
consistent with the information that would be available 
based on the MM analysis of their EBUS-TBNA samples. 
The stage IA patient was treated with SBRT and the stage 
IB patient was treated with chemotherapy and conventional 
radiation therapy as the lesion was deemed too close to the 
esophagus for treatment with SBRT. 
The presence of detectible micrometastases was 
associated with significantly worsened overall mortality and 
progression-free mortality in all patients (Table 3) and when 
limiting the analysis to stage 1 and 2 patients only (Table 4, 
Figure 2).
Figure 1 Detection of lymph node micrometastasis from endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-
TBNA) samples. (A) and (B) are two cases in which the hematoxylin and eosin (left column) staining was interpreted as negative, however 
pan-cytokeratin immunohistochemistry (center column) detected evidence of lymph node micrometastasis (small box). The right column 
demonstrates evidence of atypical cells that have dense membranous staining of pan-cytokeratin, consist with malignant carcinoma. 
Magnifications are 10×, 20×, and 40× from left to right.
A
B
Table 3 All patient outcomes
Characteristics Micrometastases (−) (n=41) Micrometastases (+) (n=3) P
Progression free survival 1,293 [399–†] 210 [115–210] 0.0093
Probability of survival at 1 year 0.75 ± 0.07 0‡
Overall survival 1,120 [440–†] 239 [172–306] 0.0357
Data are presented as median (25–75% IQR) or survival probability ± standard error. †, no 3rd quartile exists for survival as the probability  
of remaining progression free or survival for patients in this group is greater than 25% throughout the time of observation. ‡, no range  
given as all patients in the group died before 1 year.
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Figure 2 Overall and relapse-free survival for all patients and for Stages 1-2. (A) Overall survival, all patients; (B) relapse-free survival, all 
patients; (C) overall survival, stage 1 and 2 patients only; (D) relapse-free survival, stage 1 and 2 patients only.
Table 4 Clinical stage 1 and 2 patient outcomes
Characteristics Micrometastases (−) (n=36) Micrometastases (+) (n=3) P
Progression free survival 1,293 [414–†] 210 [115–210] 0.0010
Probability of survival at 1 year 0.77±0.07 0‡
Overall survival 1,120 [440–†] 239 [172–306] 0.0217
Data are presented as median (q1–q3) or survival probability ± standard error. †, no 3rd quartile exists for survival as the probability of  
remaining progression free or survival for patients in this group is greater than 25% throughout the time of observation. ‡, no range given 
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Our findings suggest that NSCLC LN MMs can be 
detected using IHC staining for pan-cytokeratin in EBUS-
TBNA specimens, and that their presence is associated 
with a worsened progression-free and overall survival. This 
finding is important as EBUS-TBNA is routinely used as a 
first line staging modality for invasive mediastinal staging 
in multiple clinical scenarios, including in patients with a 
high likelihood of N2 or N3 disease and in patients unable 
or unwilling to undergo surgical therapy but in whom 
definitive radiation therapy is planned (12,18,19). 
Several groups have examined endoscopic fine needle 
aspiration specimens of the LNs of NSCLC patients 
for the presence of MM using ancillary techniques such 
as reverse transcription polymerase chain reaction (RT-
PCR) and flow cytometry (22-25). These studies were 
conducted with the premise that the addition of RT-
PCR or flow cytometry to standard H+E staining of the 
endoscopic FNA specimens could increase the sensitivity of 
detection. Wallace et al. examined endoscopic ultrasound-
guided aspirations of mediastinal LNs for the presence 
of MM by measuring expression of a 6-gene panel. They 
detected relevant expression of at least 1 of the 6 genes in 
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30% of patients (22). RT-PCR detection of members of 
the melanoma antigen proteins (MAGE) was reported in 
the EBUS-TBNA specimens of 8% to 49% of LNs by one 
group (23,24). The addition of RT-PCR data from MAGE 
1–6 and 12 expression to standard H+E staining of EBUS-
TBNA samples increased the sensitivity of the procedure 
by 11.6% (24). Another group reported that examination of 
hypermethylation of the human homeobox gene SHOX2 by 
RT-PCR increased the sensitivity and specificity of EBUS-
TBNA when combined with standard H+E staining (25). 
Notably, none of these studies correlated their findings to 
IHC evaluation of the FNA specimen or patient outcomes. 
As such, the significance of these findings is unclear, 
particularly in light of their relatively high rate of detection 
of potential MMs.
Two recent large scale, prospective trials have evaluated 
the prevalence and significance of LN MM in surgically 
resected specimens. Rusch et al. evaluated 1,047 patients 
with previously untreated, resectable stage I to IIIb disease 
deemed LN metastasis negative by H+E. LN MM were 
detected by IHC in 22.4% of patients; the presence of 
MMs was associated with worsened overall and disease-
free survival (10). Martin et al. evaluated 298 patients with 
suspected stage I NSCLC and found that LN MMs were 
detectable in 13.8% by IHC. They reported that patients 
with LN MM at N2 stations had worse survival rates. In 
addition, 69% of LNs were positive for MM using RT-PCR 
to evaluate for CEA expression. There was no correlation 
between CEA expression and patient outcomes (11). 
Our study found detectable LN MMs in 6.8% of the 
patients evaluated who were originally thought to be 
metastasis-free on initial EBUS-TBNA. There are several 
possible reasons for the discrepancy between our reported 
incidence of LN MM detection and that reported in the 
prospective surgical literature (14–22% incidence). Our 
sample size is small and the discrepancy may be the result 
of random variation. It is unclear if the deparaffinization 
required to process our specimens affects the detection of 
MMs. Sampling error of the EBUS-TBNA procedure is 
another possibility. FNA samples sample a much smaller 
proportion of tissue as compared with the entire excised 
LN. A recent analysis of 89 LNs sampled via EBUS-TBNA 
and subsequently surgically resected demonstrates two 
instances of documented sampling error in LNs biopsied 
via EBUS-TBNA in which MMs were discovered (26). 
While it is difficult to extrapolate those findings directly 
to our data, it does suggest that sampling error may have 
some role in the discrepancy as well. Given the significant 
association we found between the presence of LN MMs 
and poor prognosis, there may be benefit of the additional 
information garnered in those patients with detected LN 
MMs. The number of LN stations sampled in our study is 
consistent with that reported by Martin et al. in which 81% 
of patients had at least 3 LN stations sampled and submitted 
for central review. As such, LN sampling frequency is 
unlikely to explain the discrepancy. 
There are several important limitations to consider for 
this work. First, no matched surgical samples are available 
from the EBUS-TBNA samples to serve as a gold standard. 
Second, bronchial epithelial cells can be contaminants of 
EBUS-TBNA samples as the needle must pass through 
the bronchial wall to sample LNs. Bronchial epithelial 
cells stain positively with CK antibodies in cell block 
samples. However, benign bronchial epithelium is usually 
easily distinguished from malignancy by an experienced 
cytopathologist. It is worth noting that CK19 mRNA 
was detected in 98% of EBUS-TBNA samples evaluated 
with RT-PCR by one group, consistent with some level 
of contamination of the specimens (23). The worsened 
disease-free and overall survival outcomes noted in our 
LN MM-positive patients argues against contamination as 
the explanation for our findings and bolsters the argument 
that pan-cytokeratin positive cells represent true LN 
MMs. Perhaps further exploration of the use of RT-PCR 
can help increase the specificity of this technique without 
compromising future sensitivity. Other limitations include 
the lack of prospective evaluation and the semi-systematic 
patient selection methodology. Although the patient’s LN 
MM status and outcome were not known at the time of 
selection for inclusion a selection bias risk remains. 
In summary, we have demonstrated that LN MMs can 
be detected in a subset of NSCLC patients sampled with 
EBUS-TBNA using pan-cytokeratin IHC. In addition, 
the presence of occult LN MMs is associated with 
significantly worse prognosis in this small study. Further 
work should focus on the validation of these findings in a 
larger prospective cohort with a focus on the non-surgical 
candidate population and methods for improving the 
sensitivity of MM detection via EBUS-TBNA.
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